In Vitro Diagnostics Products Sales

In Vitro Diagnostics Products Sales Market Outlook

The global in vitro diagnostics (IVD) products sales market is projected to reach approximately USD 113.2 billion by 2035, growing at a compound annual growth rate (CAGR) of around 6.1% during the forecast period from 2025 to 2035. The growth of this market is primarily driven by the increasing prevalence of chronic diseases, advancements in technology, and heightened awareness regarding early disease diagnosis. Moreover, the rising geriatric population, which is more susceptible to diseases, along with the growing demand for home healthcare and point-of-care testing, significantly contributes to market expansion. Additionally, the COVID-19 pandemic has propelled the shift toward diagnostics testing, further enhancing the market landscape as healthcare institutions prioritize rapid and accurate diagnostics to manage patient care effectively. Collectively, these factors create a robust framework for the growth of the IVD market.

Growth Factor of the Market

Numerous growth factors are driving the in vitro diagnostics products sales market, making it a vibrant sector within healthcare. One of the most significant factors is the continual innovation in diagnostic technologies, which has led to more accurate, rapid, and cost-effective testing solutions. The integration of automation in laboratories and point-of-care testing devices has streamlined the diagnostic process, enhancing efficiency and reducing turnaround times. Furthermore, the rising incidences of infectious diseases and chronic conditions such as diabetes and cancer have compelled healthcare systems to adopt advanced diagnostics, fueling market demand. Another contributing factor is the increasing focus on personalized medicine, whereby diagnostics are used to tailor treatments to individual patients, thus improving healthcare outcomes. The growing investments in research and development by both public and private sectors are also fostering innovation, thus accelerating market growth.

Key Highlights of the Market

• The IVD market is projected to grow at a CAGR of 6.1% from 2025 to 2035.
• The growing prevalence of chronic and infectious diseases is a major driving force.
• Technological advancements are enhancing the accuracy and efficiency of diagnostics.
• Rising investments in healthcare research and development are fostering innovation.
• Increased focus on home healthcare and point-of-care testing is expanding market opportunities.

By Product Type

Reagents & Kits:

Reagents and kits represent a significant segment of the in vitro diagnostics products sales market, primarily due to their widespread use in various testing applications. These products are essential for conducting tests across different areas, including infectious diseases, oncology, and metabolic disorders. The demand for reagents and kits is bolstered by the increasing number of diagnostic tests being performed globally, particularly with the rise in laboratory automation and the integration of digital health solutions. They are pivotal in ensuring accurate results, thus improving patient outcomes and facilitating timely clinical decisions. Furthermore, the continuous development of new reagents tailored for specific diseases is contributing positively to market growth.

Instruments:

The instruments segment of the IVD products market includes a wide array of devices such as analyzers, microscopes, and other laboratory equipment. The demand for advanced instruments is surging, driven by the need for high-throughput testing capabilities and the rapid evolution of technology in laboratory settings. Innovations in instrumentation, such as the introduction of portable and user-friendly devices, are facilitating point-of-care testing and enhancing diagnostic efficiency in various healthcare settings. As healthcare systems globally shift towards automation, the instruments used in IVD are being designed to improve accuracy and reduce human error, which is a key factor contributing to the growth of this segment.

Services:

The services segment encompasses a range of offerings, including maintenance, calibration, and training associated with in vitro diagnostic equipment. As laboratories and healthcare facilities increasingly adopt complex diagnostic technologies, there is a growing necessity for specialized services to ensure optimal performance of these instruments. This segment is anticipated to experience growth as the IVD landscape evolves, with service providers enhancing their offerings to include comprehensive support packages that address the specific needs of healthcare and laboratory professionals. Moreover, the focus on quality assurance and compliance with regulatory standards is driving the demand for professional services, thereby contributing to market expansion.

By Application

Infectious Diseases:

The application of in vitro diagnostics products in the field of infectious diseases is one of the largest segments within the market. The increasing prevalence of infectious diseases globally, combined with the urgent need for rapid and accurate diagnostics, drives this segment's growth. For instance, the ongoing emphasis on screening and diagnosing diseases such as COVID-19, HIV, and tuberculosis has led to a surge in demand for diagnostic tests. Moreover, advancements in molecular diagnostics have enabled the development of highly sensitive tests that can be performed quickly, enhancing the ability to control outbreaks and improve patient management. As public health initiatives continue to prioritize infectious disease control, this application segment is expected to grow steadily.

Cancer:

In vitro diagnostics play a crucial role in oncology, helping with the early detection of cancer, prognosis, and monitoring treatment responses. The cancer application segment is witnessing substantial growth due to the increasing global incidence of various cancer types. With advancements in technology, particularly in liquid biopsy and genomic testing, healthcare providers can now obtain vital information on tumor characteristics with minimal invasiveness. This shift toward personalized cancer treatment, supported by accurate diagnostics, is expected to drive demand in this segment. Furthermore, as awareness about cancer screening increases, the adoption of IVD products for cancer detection is anticipated to rise significantly over the forecast period.

Diabetes:

The diabetes application segment remains a critical area for in vitro diagnostics, primarily driven by the rising prevalence of diabetes globally. The increasing number of diabetes cases necessitates regular monitoring and management, leading to a heightened demand for diagnostic products such as blood glucose monitors and hemoglobin A1c tests. Advances in technology have led to the development of more user-friendly and accurate monitoring devices, making it easier for patients to manage their condition. Additionally, the focus on preventive healthcare and early diagnosis is supporting the growth of IVD products related to diabetes, as healthcare professionals aim to provide effective treatment plans tailored to individual patient needs.

Autoimmune Diseases:

Autoimmune diseases represent a growing application area for in vitro diagnostics, with an increasing recognition of the need for accurate and timely diagnosis in these conditions. The complexity and variability of autoimmune diseases can make diagnosis challenging, thus enhancing the demand for specialized diagnostic tests. The market for IVD products in this segment is expanding as healthcare providers seek reliable tests that can help identify specific autoimmune conditions. With ongoing research and development efforts aimed at producing more precise and targeted diagnostic solutions, the autoimmune diseases application segment is expected to see significant growth in the upcoming years.

Others:

The others application segment comprises various diagnostic tests that do not fall into the primary categories of infectious diseases, cancer, diabetes, and autoimmune diseases. This segment includes tests related to cardiovascular diseases, metabolic disorders, and genetic conditions. As the healthcare landscape evolves, there is an increasing emphasis on comprehensive diagnostics that encompass a wide range of conditions, thus driving the growth of this segment. Innovations in technology and the development of multi-analyte tests are enhancing this segment's capability to provide holistic health assessments, catering to the diverse needs of healthcare professionals and patients alike.

By End User

Hospitals:

Hospitals are one of the primary end users of in vitro diagnostics products, as they require a continuous supply of diagnostic tests to ensure the timely and accurate diagnosis of patients. The increasing patient volume in hospitals, driven by an aging population and the rise in chronic diseases, is significantly boosting the demand for IVD products. Additionally, advancements in hospital laboratory automation and integration with electronic health records are enhancing the efficiency and accuracy of diagnostics within hospital settings. The focus on patient-centered care and rapid decision-making further emphasizes the necessity for reliable in vitro diagnostic solutions, making hospitals a crucial segment for market growth.

Clinical Laboratories:

Clinical laboratories play a pivotal role in the in vitro diagnostics market, performing a wide range of diagnostic tests that support healthcare providers in making informed clinical decisions. The increasing reliance on clinical laboratories for accurate and timely diagnostics is driving the growth of this end-user segment. Moreover, with the growing trend of outsourcing laboratory services, many hospitals and healthcare facilities are turning to clinical laboratories for specialized testing, thereby increasing market demand. The ongoing advancements in laboratory technologies and the expansion of testing capabilities within clinical laboratories are also significant contributors to the growth of this sector.

Academic & Research Institutes:

Academic and research institutes are key players in the in vitro diagnostics products market, primarily involved in the development, validation, and implementation of new diagnostic technologies. The collaboration between these institutions and the healthcare industry fosters innovation and enhances the overall quality of diagnostics. The increasing focus on research and development, particularly in fields such as genomics and proteomics, is leading to the introduction of advanced diagnostic products. Additionally, the rising demand for educational programs that emphasize the importance of diagnostics in healthcare underpins the growth of this segment as institutions strive to improve clinical outcomes through research-driven advancements.

Others:

The others end-user segment includes a range of entities, such as home healthcare providers, pharmacies, and point-of-care testing facilities, which are becoming increasingly relevant in the landscape of in vitro diagnostics. The growing trend of home healthcare is driving demand for portable diagnostic devices, enabling patients to monitor their health conditions more conveniently. Pharmacies are also expanding their services to include diagnostic testing, further contributing to market growth. The shift towards point-of-care testing allows for immediate results, which is increasingly valued by patients and healthcare providers alike. As these alternative end-user channels continue to evolve, they will play an important role in shaping the future of the IVD products market.

By Technology

Immunoassay:

Immunoassay technology is one of the most widely used techniques in in vitro diagnostics, primarily for its ability to detect specific biomarkers in samples. This technology harnesses the specificity of antibodies to identify and quantify various substances, such as hormones, drugs, and proteins, playing a critical role in disease diagnosis and monitoring. The growth of immunoassays is driven by their versatility and accuracy, making them essential in clinical laboratories and point-of-care settings. Additionally, advancements in this technology, such as the development of high-throughput screening methods, continue to enhance its applicability and efficiency, further propelling the market for immunoassay-based diagnostics.

Molecular Diagnostics:

Molecular diagnostics represent a rapidly growing segment within in vitro diagnostics, providing precise and timely information on genetic disorders, infectious diseases, and cancers. This technology utilizes techniques such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) to analyze nucleic acids, enabling the detection of specific pathogens or genetic mutations. The increasing prevalence of infectious diseases, along with the rising demand for personalized medicine, is significantly driving the growth of molecular diagnostics. The continuous advancements in molecular technology are also enhancing sensitivity and specificity, reinforcing the importance of this segment in the overall IVD market.

Clinical Chemistry:

Clinical chemistry is a fundamental aspect of in vitro diagnostics, focusing on the analysis of bodily fluids to inform patient care. This technology encompasses a variety of tests that assess metabolic functions, organ health, and disease markers, making it integral to clinical decision-making. The demand for clinical chemistry tests continues to rise due to the increasing rates of chronic diseases and the need for routine health monitoring. Innovations in analytical techniques and instrumentation are enhancing the efficiency and accuracy of clinical chemistry testing, further supporting the growth of this segment. As healthcare providers increasingly rely on clinical chemistry to guide treatment decisions, its significance in the IVD market will continue to expand.

Microbiology:

The microbiology segment of in vitro diagnostics involves the detection and identification of microorganisms causing infectious diseases. This area is crucial in diagnosing bacterial, viral, and fungal infections, guiding appropriate treatments. The increasing incidence of infectious diseases, compounded by concerns over antibiotic resistance, drives the demand for microbiology diagnostics. Additionally, advancements in technologies, such as automated culture systems and molecular methods, are enhancing the speed and accuracy of microbiological testing. As the focus on infection control and prevention intensifies in healthcare settings, the microbiology segment will play an increasingly vital role in the in vitro diagnostics landscape.

Others:

The others technology segment encompasses various diagnostic techniques that do not fall under the primary categories of immunoassay, molecular diagnostics, clinical chemistry, and microbiology. This segment includes emerging technologies like biosensors, point-of-care testing devices, and lab-on-a-chip systems, which are gaining traction due to their ability to provide rapid and accurate results. The growing emphasis on decentralized healthcare and the need for immediate diagnostic information are driving the adoption of these innovative technologies. As healthcare continues to evolve, the others technology segment will play a crucial role in enhancing accessibility and efficiency within the in vitro diagnostics market.

By Region

The regional analysis of the in vitro diagnostics products sales market reveals significant variations in growth dynamics across different areas. North America currently dominates the market, accounting for over 40% of the global share, driven by the presence of advanced healthcare infrastructure, high healthcare expenditure, and a strong emphasis on research and development. The U.S. market is particularly robust, supported by the increasing prevalence of chronic diseases and the growing demand for technologically advanced diagnostic solutions. The CAGR for the North American region is projected to be around 5.8% from 2025 to 2035, fueled by innovations in diagnostic technologies and the continuous expansion of healthcare services.

Europe holds the second-largest market share in the in vitro diagnostics products sales market, representing approximately 30% of total revenue. The growth in this region is attributed to the rising healthcare expenditure, an increasing aging population, and the heightened awareness regarding early disease detection. The European market is characterized by stringent regulatory frameworks that promote the use of high-quality diagnostic products. The Asia Pacific region is also emerging as a significant market, expected to witness a CAGR of 7.2% during the forecast period, driven by improving healthcare infrastructure, rising disposable incomes, and growing investments in healthcare technology. As countries in the region continue to prioritize healthcare improvements, their contribution to the global IVD market will increase significantly.

Opportunities

The in vitro diagnostics market is poised to experience numerous opportunities as the healthcare landscape continues to evolve. One significant opportunity lies in the growing demand for personalized medicine, which relies heavily on diagnostic testing to tailor treatments to individual patient profiles. As advancements in genomics and molecular diagnostics progress, there is potential for the development of more targeted therapies, thus bolstering the market for IVD products. Furthermore, the increasing prevalence of chronic diseases, coupled with the aging population, presents a vast opportunity for the expansion of diagnostic testing. The focus on preventive healthcare and early diagnosis strategies is pushing healthcare systems to invest in advanced diagnostics; thereby, creating opportunities for manufacturers to develop innovative solutions that address these needs.

Another opportunity arises from the proliferation of point-of-care (POC) testing, which allows for immediate diagnostic results in various settings, including clinics, pharmacies, and home healthcare. This trend is driven by the growing demand for rapid testing solutions, particularly in light of the recent pandemic, which highlighted the necessity for agile healthcare responses. As POC testing continues to gain acceptance among healthcare providers and patients alike, there is a significant opportunity for IVD manufacturers to develop portable, user-friendly diagnostic devices. Additionally, the rising trend of telemedicine further complements this opportunity, as patients increasingly seek remote care solutions, thus enhancing the need for accessible and accurate diagnostic tools.

Threats

Despite the promising outlook for the in vitro diagnostics products sales market, several threats could impact its growth trajectory. One of the most pressing concerns is the stringent regulatory environment surrounding diagnostic products, which can delay product approvals and increase costs for manufacturers. Compliance with evolving regulations necessitates significant investments in quality assurance and validation processes, potentially limiting the capacity of smaller companies to compete in the market. Additionally, the rapid pace of technological advancements poses a challenge for established players to keep up with emerging competitors that may introduce disruptive innovations. The threat of market saturation, particularly in mature markets such as North America and Europe, could also hinder growth prospects, compelling companies to continually innovate to maintain their market position.

Another potential threat comes from the rising prevalence of counterfeit diagnostic products, which can undermine trust in the healthcare system and adversely affect patient safety. The emergence of low-quality products in the market poses risks not only to patient health but also to the reputation of legitimate manufacturers. Furthermore, economic fluctuations and changes in healthcare policies can affect funding and reimbursement for diagnostic tests, impacting the overall market dynamics. As the healthcare landscape continues to evolve, companies in the in vitro diagnostics sector will need to navigate these challenges effectively to sustain long-term growth.

Competitor Outlook

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Danaher Corporation
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories
• Cepheid (A Danaher Company)
• Ortho Clinical Diagnostics
• Hologic, Inc.
• Sysmex Corporation
• Grifols, S.A.
• PerkinElmer, Inc.
• QIAGEN N.V.
• Mindray Medical International Limited

The competitive landscape of the in vitro diagnostics products sales market is characterized by a mix of established players and emerging innovators. Leading companies such as Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers hold significant market shares, driven by their extensive portfolios of diagnostic products and ongoing investments in research and development. These companies are constantly striving to enhance their product offerings by incorporating cutting-edge technologies, such as artificial intelligence and automation, to improve diagnostic accuracy and efficiency. Their strong presence in global markets, combined with strategic partnerships and collaborations, enables them to maintain a competitive edge and cater to diverse healthcare needs across various regions.

Emerging players such as Cepheid and QIAGEN N.V. are also making significant strides in the in vitro diagnostics market, particularly in molecular diagnostics and point-of-care testing. Their focus on innovative technologies and agile product development allows them to respond to market demands swiftly. These companies are leveraging advancements in genomics and molecular biology to create high-quality diagnostic solutions that meet the evolving requirements of healthcare providers. The competitive dynamics in the IVD market are continually shifting, as companies seek to capitalize on opportunities arising from the growing demand for personalized medicine and rapid diagnostics.

Furthermore, the ongoing trend of mergers and acquisitions within the IVD industry is reshaping the competitive landscape. Companies are seeking to expand their product portfolios and geographic reach by acquiring smaller firms with specialized technologies. For instance, Danaher Corporation's acquisition of Cepheid showcases a strategic move to enhance their molecular diagnostics capabilities. This consolidation trend is likely to continue as companies aim to strengthen their positions in the market and leverage synergies to drive innovation. Overall, the in vitro diagnostics products sales market presents a dynamic and competitive environment, with ample opportunities for both established and emerging players to thrive.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 QIAGEN N.V.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Grifols, S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Hologic, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 PerkinElmer, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Roche Diagnostics
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sysmex Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Danaher Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Bio-Rad Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Thermo Fisher Scientific
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Ortho Clinical Diagnostics
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Cepheid (A Danaher Company)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 BD (Becton, Dickinson and Company)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Mindray Medical International Limited
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 In Vitro Diagnostics Products Sales Market, By End User
    • 6.1.1 Hospitals
    • 6.1.2 Clinical Laboratories
    • 6.1.3 Academic & Research Institutes
    • 6.1.4 Others
  • 6.2 In Vitro Diagnostics Products Sales Market, By Technology
    • 6.2.1 Immunoassay
    • 6.2.2 Molecular Diagnostics
    • 6.2.3 Clinical Chemistry
    • 6.2.4 Microbiology
    • 6.2.5 Others
  • 6.3 In Vitro Diagnostics Products Sales Market, By Application
    • 6.3.1 Infectious Diseases
    • 6.3.2 Cancer
    • 6.3.3 Diabetes
    • 6.3.4 Autoimmune Diseases
    • 6.3.5 Others
  • 6.4 In Vitro Diagnostics Products Sales Market, By Product Type
    • 6.4.1 Reagents & Kits
    • 6.4.2 Instruments
    • 6.4.3 Services

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 In Vitro Diagnostics Products Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global In Vitro Diagnostics Products Sales market is categorized based on

By Product Type

• Reagents & Kits
• Instruments
• Services

By Application

• Infectious Diseases
• Cancer
• Diabetes
• Autoimmune Diseases
• Others

By End User

• Hospitals
• Clinical Laboratories
• Academic & Research Institutes
• Others

By Technology

• Immunoassay
• Molecular Diagnostics
• Clinical Chemistry
• Microbiology
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• Thermo Fisher Scientific
• Danaher Corporation
• BD (Becton, Dickinson and Company)
• Bio-Rad Laboratories
• Cepheid (A Danaher Company)
• Ortho Clinical Diagnostics
• Hologic, Inc.
• Sysmex Corporation
• Grifols, S.A.
• PerkinElmer, Inc.
• QIAGEN N.V.
• Mindray Medical International Limited